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cells in serum-containing conditioned medium 
reveals CCT8 as a new biomarker of pancreatic 
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Abstract 
Background: Pancreatic cancer is a malignancy with a very poor prognosis. The emergence of liquid biopsy is 
expected to achieve accurate early diagnosis through detection of tumor-derived secreted proteins in the blood. Early 
diagnosis and treatment of pancreatic cancer could help to improve prognosis.
Methods: The pretreatment approach of samples can have a major effect on downstream analysis. In this study, we 
used a pair of homologous pancreatic cancer cell supernatants with different capacities for invasion and metastasis 
to examine secreted proteins in the conditioned media without the removal of fetal bovine serum, namely through 
size exclusion chromatography combined with high-abundance protein affinity chromatography to enrich low-
concentration protein, followed by mass spectrometry using triple dimethyl labeling. Identification of proteins was 
performed using an online public database and western blot.
Results: Mass spectrometry data revealed 77 proteins with quantitative properties, of which 12 proteins had over 
a 1.5-fold difference (in the supernatant of the highly invasive pancreatic cancer cell line PC-1.0, the expression of 
8 proteins were increased and the expression of 4 proteins were decreased). Bioinformatics analysis results showed 
that CCT8, CTSL, SAA1, IGF2 are secreted via the exosome pathway. According to the literature, with the exception of 
CCT8, the other three proteins can be detected in blood samples of pancreatic cancer patients, and they can be used 
as prognostic markers. Western blot results were used to validate consistency with MS results.
Conclusion: This study found that CCT8 can be used as a liquid biopsy marker to assess the prognosis of pancreatic 
cancer patients.
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Background
Pancreatic cancer ranks fourth in cancer mortality in the 
United States. In 2019, 56,770 new cases of pancreatic 
cancer are expected in the United States. Due to its ana-
tomical location deep in the abdominal cavity, patients 
do not present unique symptoms, and most tumors are at 
an advanced stage at the time of diagnosis and are often 
accompanied by vascular invasion or distant metastasis. 
Surgical treatment is an option in only 15–20% of pan-
creatic cancer patients, and the overall 5-year survival 
rate is less than 5% [1, 2]. Early diagnosis and appropri-
ate treatment can significantly improve the prognosis of 
pancreatic cancer. With the advancement of experimen-
tal techniques, the number of molecular and chemical 
detection methods for pancreatic cancer has increased, 
and these methods have played an important role in the 
early diagnosis of pancreatic cancer [3].
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Tumor microenvironment can regulate cancer develop-
ment and metastasis. Hanahan et  al. have reported that 
heterogeneous signaling pathways between the paren-
chyma and mesenchyme of a tumor play an important 
role in tumor invasion and metastasis [4]. Studies have 
confirmed that secreted proteins play an important role 
in the tumor microenvironment [5]. In previous studies, 
we used two cell lines with distinct capacities for inva-
sion and metastasis: a non-dissociated, weakly meta-
static pancreatic cancer cell line (PC-1) and a dissociated, 
highly metastatic pancreatic cancer cell line (PC-1.0). 
PC-1.0 cell supernatant was purified, prepared into a 
conditioned medium, and used for culture of the weakly 
metastatic PC-1 cells. It was found that the growth of 
PC-1 cells changed to the growth pattern of PC-1.0. 
Therefore, we concluded that PC-1.0 supernatant con-
tains key factors that promote changes in the biological 
behavior of the cells [6].
In this study, the secretome was extracted from the 
serum-containing supernatant, and low-abundance pro-
teins were enriched by online chromatographic separa-
tion. In addition, the pancreatic cancer secretome was 
analyzed in combination with triple dimethyl labeling. 77 
proteins were identified, of which 12 with a fold change 
of over 1.5 were considered differentially expressed pro-
teins. DAVID and STRING software were used to analyze 
the function of differential proteins and their possible 
interacting proteins. Survival analysis of these differen-
tial genes was performed using a public pancreatic can-
cer database. Finally, we selected CCT8 and CTSL for 
protein validation in two pairs of cell lines with different 
capacities for invasion and metastasis.
Materials and methods
Instruments, reagents, and materials
Acetonitrile (ACN) and methanol were purchased from 
Merck (Germany). Glacial acetic acid was purchased 
from Damao Chemical Reagent Factory (Tianjin, China). 
Bovine serum albumin (BSA), formaldehyde and its iso-
topic reagents  (CH2O, 13CH2O, 13CD2O,  CD2O), sodium 
cyanoborohydride  (NaBH3CN), deuterated sodium cyan-
oborohydride  (NaBD3CN), heavy water  (D2O), α-cyano-
4-hydroxycinnamic acid (CHCA), and trifluoro acetic 
acid (TFA) were purchased from Sigma-Aldrich (USA). 
All water for experiments was purified using the Milli-Q 
system (Millipore, USA). The centrifuge was purchased 
from Sigma (USA). The Thermo SEC120 HPLC column 
(size 5 μm, 120 Å) and Agilent Human 14 Multiple Affin-
ity Removal Column (H14, size: 10 mm × 100 mm) were 
used. The Ultimate 3000 chromatography instrument was 
used with the Thermo LTQ-Orbitrap mass spectrometer 
for detection.
Cell culture
PC-1.0 and PC-1 cells were given friendly by Kuma-
moto University Medical School (Kumamoto, Japan) 
and the use of these cell lines was approved by China 
Medical University Affiliated Shengjing Hospital Medi-
cal Research. Aspc-1, Capan-2 cells, and HPDE6-C7 
were purchased from the Institute of Biochemistry and 
Cell Biology, Chinese Academy of Sciences (Shanghai, 
P.R. China). PC-1 cells grew as islet-like clones of cells, 
whereas PC-1.0 cells grew as single cells. These cells were 
cultured in RPMI-1640 (Gibco-BRL, Grand Island, NY) 
supplemented with 10% fetal bovine serum + 1% strep-
tomycin. Cells were incubated in a 37 °C incubator with 
5%  CO2. Cells were passaged when they reached a conflu-
ence of about 80% [7].
Experimental methods
Extraction of total protein from samples
PC-1.0 and PC-1 cells were cultured in complete growth 
medium until 80–90% confluent. The supernatant was 
collected and protease inhibitors were added. The super-
natant was centrifuged at 500g and 3000g for 15 min to 
remove debris. The mixture was spun at 12000 r/min 
through a 0.22  μm fiber filter and concentrated using a 
3  kDa concentrating tube by centrifuging at 3500g for 
120  min. Protein samples included three independent 
biological replicates. Protein concentration was meas-
ured using the BCA method. The experimental process is 
shown in Fig. 1.
SEC and H14 sample isolation
High-abundance proteins were removed using a size 
exclusion chromatography (SEC) column combined with 
an Agilent multiple affinity removal spin cartridge (H14) 
to enrich low-abundance proteins. A 200  μL sample 
was injected and washed with buffer A at a flow rate of 
0.5 mL/min for 10 min. After the flow through fractions 
were collected, the remaining fractions were eluted with 
buffer B at 1 mL/min for 7 min. The collected fractions 
were stored at − 20  °C until use. The flow through frac-
tions collected from the injection were concentrated in a 
rotary concentrator with a 5 kDa molecular weight cut-
off membrane. The sample was centrifuged at 5000 r/min 
at 10 °C.
Triple dimethyl labeling
Protein concentration was measured using the BCA 
method, and samples were prepared using FASP. PC-1.0 
cells were labeled with 50 mM pH 8.0 phosphate buffer 
with 20  μL of 4% formaldehyde and 20  μL of 0.6  M 
sodium cyanoborohydride (light label) added. PC-1 cells 
were labeled with 20  µL 4% deuterated formaldehyde 
and 20 μL of 0.6 M sodium cyanoborohydride (medium 
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label). 1640 medium was labeled with 20  μL of 4% 
13CD2O and 20 μL of 0.6 M deuterated sodium cyanob-
orohydride (heavy label). The reaction was conducted at 
room temperature for 1 h. Labeled solutions were com-
bined, lyophilized and stored at -20 °C.
Capillary liquid chromatography‑mass spectrometry analysis 
and database search
The Ultimate 3000 chromatography instrument was used 
with the Thermo LTQ-Orbitrap mass spectrometer. The 
flow direction was divided into an A phase (98%  H2O 
and 2% ACN with 0.1% formic acid) and a B phase (2% 
 H2O and 98% ACN with 0.1% formic acid). We used a 
custom C18 capillary trap column (150 μm inner diame-
ter × 4 cm) and a separation column (75 μm inner diame-
ter × 15 cm) with a flow rate of 120 μL/min. Mobile phase 
setting: 0–6% B phase for 10  min, then 6–35% B phase 
for 100 min, 35–80% B phase for 10 min, and finally 80% 
B phase for 10 min. The voltage was set to 2.7 kV and the 
ion transfer capillary temperature was 275 °C. Mass spec-
trometry was sequenced in a data-dependent manner. 
The CID ion dissociation method was used, a dynamic 
20-second exclusion window was set, and the mass spec-
trometry ion mass-to-charge ratio scan range was from 
300 to 1800. Samples were measured in triplicate. The 
experimentally obtained mass spectra were searched 
using Maxquant software to analyze the data files (.RAW) 
produced by the mass spectrometry. Settings for relevant 
parameters: mass error of the parent ion was 7 ppm, and 
mass error of the daughter ion was 20mmu. The fixation 
modification was an alkylation modification to cysteine, 
and the variable modification is an oxidation modifica-
tion of methionine. The maximum number of missed 
sites allowed was 2, and the FDR for peptide and protein 
identification was less than 1%.
Bioinformatics analysis
In this study, quantitative data was obtained for all three 
experiments, the p-value was < 0.05, indicating that the 
data was reliable. We considered fold differences greater 
than 1.5 to be differential expression. To elucidate the 
function of secreted proteins, we performed bioinformat-
ics analysis using DAVID (http://david .abcc.ncifc rf.gov/) 
[8] and STRING (https ://strin g-db.org/) [9] software. In 
addition, we also searched the Exocarta database [10] 
to determine if these proteins were exosomes. Finally, 
we performed a matching search on pancreatic cancer 
genomics studies publicly available so far, and observed 
the association of genes corresponding to these proteins 
with pancreatic cancer [11].
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS‑PAGE)
To an appropriate amount of protein sample solution, an 
equal volume of reducing loading buffer (2% SDS, 20% 
glycerol, 20 mmol/L Tris–HCl, pH 6.8, 6 mmol/L ß-mer-
captoethanol, a trace amount of bromophenol blue) was 
added. After boiling for 5 min, separation was performed 
using a vertical electrophoresis apparatus. After the 
Fig. 1 Conditioned media of PC-1.0 derived, PC-1 derived, and 1640 were validated by SDS-PAGE
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electrophoresis was finished, the film was stained with 
silver nitrate and scanned.
Western blot
Western blotting was performed as described previ-
ously [7]. Primary antibodies against CCT8 polyclonal 
antibody (Abcam, USA) and CTSL polyclonal antibody 
(Proteintech, USA) were used. Supernatant was collected 
when the cells reached 80–90% confluence, and protease 
inhibitors were added. The supernatant was centrifuged 
at 500g and 3000g for 15  min, the supernatant was col-
lected, proteins were concentrated using a 3 kDa concen-
trating tube, and protein concentration was measured 
using the BCA method. Samples of equivalent total pro-
tein (20 μg) were loaded.
Cell transfection
shRNA plasmid specific for CCT8, scrambled shRNA, 
and lentiviral vector were purchased from GeneChem 
(GeneChem, Shanghai, China). Stable transfection with 
lentiviral vector was performed in accordance with man-
ufacturer’s protocols. Scrambled shRNA was used as 
control.
Cell invasion and migration assays
Wound healing migration assay and Transwell invasion 
assay were performed as previously described [7].
Results
Immunoblotting detection of pancreatic cancer 
supernatant
In order to initially detect overall protein content in the 
supernatant of pancreatic cancer cells, we collected total 
protein from the supernatant and performed SDS-PAGE 
electrophoresis and silver staining (Fig.  2). The results 
showed that the approximate distribution of proteins in 
the supernatant of pancreatic cancer cells: high molecu-
lar weight proteins (greater than 44 kDa) were abundant, 
and there were fewer low molecular weight proteins (less 
than 20 kDa).
Proteins with quantitative differential expression
The experimental samples were separated using SEC and 
H14 columns to enrich the concentration of low abun-
dance proteins. A total of 77 proteins were identified 
using Maxquant software through the combined calcu-
lations of three experiments (Additional file  1: Table  S1 
and Additional file  2: Table  S2). Functional annota-
tion analysis of these proteins using DAVID revealed 
close association with cell secretion, cell proliferation, 
and migration and metastasis (Table  1). In the experi-
ment, we performed triple dimethyl labeling, namely, 
supernatants of highly invasive PC-1.0 cells with a light 
label, supernatants of weakly invasive PC-1 cells with a 
medium label, and 1640 medium with a heavy standard. 
By labeling the 1640 medium, we removed interference 
from serum proteins in the medium, which enhanced 
the reliability of the identification results. Based on the 
results of the search, we considered proteins with an over 
1.5-fold change in the ratio of the three labels as signifi-
cant differentially expressed proteins. The results showed 
that there were 12 differentially expressed proteins, of 
which 8 were up-regulated and 4 were down-regulated 
(Table 2).
Gene ontology, KEGG, and PPI analysis
GO analysis was performed using online DAVID soft-
ware. The primary enrichment in cellular component 
(CC) was cytoplasmic vesicle and extracellular exo-
some, and the primary enrichment in biological process 
(BP) was the regulation of cell adhesion. The primary 
enrichment in molecular function (MF) was protein 
complex binding. Using functional annotation cluster-
ing analysis in the software, we found that the primary 
cluster was exosome signaling, which included four 
proteins (CTSL, CCT8, IGF2 and SAA1). These results 
also confirmed that we identified secreted proteins 
(Additional file  3: Table  S3). KEGG analysis showed 
that proteins were concentrated on the proteoglycans 
in cancer (p = 0.0025) signaling pathway. To further 
analyze the role of the identified proteins, we used 
the STRING database to search for DEPs. The results 
Fig. 2 PPI network analysis of differentially expressed secretome 
proteins from PC-1.0 and PC-1 cells
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showed that there is currently no literature support 
for interaction between the eight proteins, which may 
be due to the small number of proteins we identified. 
Therefore, we used the increased protein interaction 
function built into the software. It was found that as the 
software gradually increased protein interaction, SAA1 
and CCT8 could interact through GNB1, CCT8 and 
EXOSC8 were linked by EXOSC3, and CTSL and IGF2 
were linked by IGFGB3. Therefore, through data min-
ing, we believe that CCT8 may be a key protein in this 
PPI network (Fig. 3, Additional file 4: Table S4).
Possible clinical significance of differential proteins
We used the Human Protein Atlas database to search 
CCT8, CTSL, IGF2, and SAA1 for clinical correlation 
analysis. Using clinical data on pancreatic cancer pro-
vided by Pathology Atlas, we analyzed the FRKM val-
ues of the four genes and found that CCT8 and IGF2 
were associated with clinical prognosis (p = 0.018, 
p = 0.0001) (Fig.  4, Additional file  5: Table  S5). There 
have been no literature reports of the function of CCT8 
in pancreatic cancer. We searched the Exocarta data-
base and our results from exosome studies, as well as 
these four proteins [12], which revealed from a differ-
ent perspective that the four secreted proteins were 
secreted outside the cell in the form of exosomes. 
According to currently available public data, these four 
secreted proteins are present in human plasma samples 
and can be used as liquid biopsy markers in the future.
Western blot validation of the expression of differentially 
expressed proteins in cell lines with different capacities 
for invasion and metastasis
We used two pairs of cell lines (PC-1.0 vs. PC-1 and 
Aspc-1 vs. Capan-2) to measure intracellular CTSL 
and CCT8 protein expression. The results showed that 
CTSL and CCT8 were highly expressed in the highly 
invasive PC-1.0 and Aspc-1 cell lines (Fig. 5). This result 
is consistent with mass spectroscopy.
Knockdown of CCT8 suppressed the migration 
and invasion capabilities
To investigate the potential role of CCT8 in the 
metastasis of pancreatic cancer, we knocked down 
Table 1 DAVID revealed close association with cell secretion, cell proliferation, and migration and metastasis
Category Term P-value Fold enrichment
Annotation Cluster 1 Enrichment Score: 15.7
UP_KEYWORDS Secreted 5.81E−26 12.93408
Annotation Cluster 2 Enrichment Score: 3.3
GOTERM_MF_DIRECT GO:0031994 ~ insulin-like growth factor I binding 1.29E−04 163.6875
Annotation Cluster 3 Enrichment Score: 3.0
KEGG_PATHWAY bta04610:Complement and coagulation cascades 6.54E−05 21.25563
Annotation Cluster 4 Enrichment Score: 2.6
UP_KEYWORDS Extracellular matrix 1.02E−05 20.19811
Annotation Cluster 5 Enrichment Score: 2.5
GOTERM_CC_DIRECT GO:0005604 ~ basement membrane 0.009647 19.7711
Annotation Cluster 6 Enrichment Score: 1.9
KEGG_PATHWAY bta04510:Focal adhesion 0.003284 7.562099
Annotation Cluster 7 Enrichment Score: 1.8
UP_SEQ_FEATURE Domain:Peptidase S1 0.002328 14.57442
Table 2 List of  12 proteins differentially expression 
by  PC-1.0 and  PC-1 pancreatic cancer cells with  fold 
change > 1.5
Protein Ratio L/M  
(PC-1.0/PC-1)
Ratio L/H  
(PC-1.0/1640)
Ratio M/H 
(PC-1/1640)
SAA1 6.96 1.56 0.22
Roquin-1 3.29 1.52 0.55
CCT8 2.74 1.91 0.63
ZNF518B 2.14 4.39 1.85
CTSL 1.77 17.12 10.46
EXOSC8 1.60 3.16 2.57
IGF2 1.61 0.64 0.43
C4orf470 1.62 0.47 0.32
Npc2 0.57 8.55 13.36
HSP90AA1 0.45 0.66 1.54
PPIA 0.10 1.80 18.16
ENO1 0.05 1.89 31.58
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the expression of CCT8 in PC-1.0 and AsPC-1 cell 
lines. In  vitro migration and invasion assay showed 
that knockdown of CCT8 suppressed the migration 
and invasion capabilities of PC-1.0 and AsPC-1 cells 
(Figs.  6, 7). These results suggested that knockdown 
of CCT8 could suppress the metastatic phenotype of 
these two pancreatic cancer cell lines.
Discussion
When tumor cells secrete proteins into the extracel-
lular environment, some of these proteins can alter the 
tumor microenvironment to promote tumor growth [13]. 
Previous studies have also confirmed some tumor bio-
markers through secretome analysis. Most proteomic 
studies were performed in serum-free medium. These 
studies have used serum starvation to reduce interfer-
ence from a large number of serum proteins and have 
found many biomarkers, but many significant limitations 
still exist [14, 15]. For example, many secreted proteins 
in culture media can cause changes in secretion status 
even during the short-term serum starvation process 
[16]. The pretreatment approach can have a major impact 
on downstream analysis. Therefore, we did not perform 
serum starvation in our experiments. In order to reduce 
Fig. 3 CCT8 is a key protein in this network
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the effects of high-abundance proteins, the secreted pro-
teins in the supernatant were separated using the SEC 
and H14 columns, and the results were thus more reliable 
(Fig. 8).Based on the results of previous experiments, cell 
biological changes can occur between pancreatic cancer 
cells with different capacities for invasion. The difference 
between the secretomes produced by two cell lines is 
very important for understanding the molecular mecha-
nism of tumor cell invasion and metastasis.
Through GO and KEGG analysis, it was confirmed that 
the main functions of the differential proteins were con-
centrated in cell secretion, which increased the reliability 
of our experimental results. It is well known that tumor 
development and progression occurs over three stages, 
of which cellular cancerous transformation is the best 
stage for monitoring and treatment. Liquid biopsy can be 
used to observe the risk of carcinogenesis at the cellular 
level, provide early warning, and be used for screening 
Fig. 4 Expression level and prognostic value of the differentially expressed secretome proteins in Human Protein Atlas database
Fig. 5 Western blot validation of CCT8 and CTSL from PC-1.0, PC-1, AsPC-1, Capan-2 and HPDE6-C7 cell lines (n = 3)
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of high-risk populations. Traditional pathological biopsy 
has certain risks, and these tumor biomarkers derived 
from secreted proteins can be directly detected in body 
fluids, which can help distinguish between benign and 
malignant tumors earlier and more quickly, and help 
develop more appropriate treatment plans. In addition, 
they can also suggest the existence of occult micro-
metastases in the body. For patients with metastatic 
tumors without metastasis or undiscovered metastasis, 
it can help with more accurate staging and guide clinical 
selection of more appropriate treatment methods [17].
To summarize the results of this manuscript, we have 
identified a small number of proteins, but the literature 
and our own data confirm that these differential proteins 
are secreted via exosomes, which proves that the results 
of experiments are close to the actual status of secretion. 
Fig. 6 Knockdown of CCT8 suppress migration capability in PC-1.0 and AsPC-1 cell lines (magnification, ×100) (n = 3)
Fig. 7 Knockdown of CCT8 suppress invasion capability in PC-1.0 and AsPC-1 cell lines (magnification, ×100) (n = 3)
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PPI network analysis showed that there was no direct 
relationship between these eight differential proteins. 
After data mining, we found that CCT8 is a potential 
core protein. Chaperonin-containing T-complex pro-
tein (CCT) has eight subunits, CCT1–8. The literature 
reports that CCT8 can affect invasion and metastasis of 
glioma cell carcinoma [18]. The TRic complex formed 
by CCT8 and other proteins can mediate protein fold-
ing and play an essential role in the telomerase pathway 
[19]. Currently, the relationship between the function of 
CCT8 as a secreted protein and pancreatic cancer has 
not been reported in the literature. We found through 
survival analysis that CCT8 can be used as a predictor 
of pancreatic cancer. CTSL upregulation has been found 
in many cancers to be positively associated with cancer 
invasion and metastasis and poor prognosis [20–23]. In 
addition, it has been reported in the literature that CTSL 
is highly expressed in the plasma of patients with pancre-
atic cancer and can be used as an independent predic-
tor of pancreatic cancer [24]. Toriola et  al. detected the 
expression of circulating IGF2 in blood, which was con-
firmed to be associated with pancreatic cancer prognosis 
[25]. SAA1 is highly expressed in cancer-associated fibro-
blasts (CAFs), and the higher the expression of SAA1 in 
the matrix composition, the worse the prognosis. Selec-
tive inhibition of SAA1 expression in CAF may provide 
potential therapeutic benefit to patients with PDAC [26]. 
In addition, detection of SAA in the blood is useful for 
distinguishing between malignant and benign diseases as 
well as healthy controls [27]. Online database suggested 
that CTSL and SAA1 were not associated with pancre-
atic cancer prognosis (p > 0.05), probably due to changes 
in protein content during tissue sample processing. Fur-
ther in vitro functional experiments showed that knock-
down of CCT8 suppressed invasion and metastasis of 
pancreatic cancer cell lines. In future studies, we will per-
form functional analysis of CCT8in vivo, while collecting 
clinical blood samples for cohort studies.
Conclusion
In this study, samples were separated using two columns 
together in conjunction with dimethyl labeling, and mass 
spectrometry were used to improve the identification of 
secreted proteins under complete-medium conditions. 
Through biological analysis and cytological validation, it 
was confirmed that circulating CCT8 is a new predictive 
biomarker for pancreatic cancer.
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